Clinical trials: Migraine
Migraine Without Aura, Migraine With Aura
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Evaluation of headache response at 2 hours for active treated attacks for increasing dose.
- Trial name
- NCT01859481
- Testing
- Eletriptan HBr 40 mg, Eletriptan HBr 80 mg
- Where
- 148 sites in Belgium, Czechia and 12 more
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
- Trial name
- NCT02959177
- Testing
- Galcanezumab
- Where
- 47 sites in Japan
- Volunteers
- 459 people
- Sponsor
- Eli Lilly and Company
Migraine Headaches
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
- Trial name
- NCT00442221
- Testing
- Sumatriptan and Naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- POZEN
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine Disorders
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
An evaluation of tablet disintegration and absorption and gastric transit of sumatriptan and naproxen sodium from a TREXIMA tablet and eletriptan from a RELPAX 40mg tablet.
- Trial name
- NCT00385008
- Testing
- Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Episodic Migraine, Chronic Migraine
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
- Trial name
- NCT04686136
- Testing
- Atogepant 60 mg
- Where
- 116 sites in United States, Canada and 12 more
- Volunteers
- 596 people
- Sponsor
- AbbVie
Migraine Headaches
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65…
- Trial name
- NCT02057315
- Testing
- ELS-M11
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Achelios Therapeutics
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Pain, Migraine Disorders
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04427429 in healthy women.
- Trial name
- NCT01511497
- Testing
- PF-04427429, Normal saline
- Where
- 3 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acute Migraine
Migraine Treatment With Nerivio Migra Neurostimulation Device
This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
- Trial name
- NCT03076515
- Testing
- Nerivio Migra neurostimulation
- Where
- 8 sites in United States, Israel
- Volunteers
- 120 people
- Sponsor
- Theranica
Migraine Disorders
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
- Trial name
- NCT03716505
- Testing
- gammaCore Sapphire active
- Where
- 30 sites in United States
- Volunteers
- 231 people
- Sponsor
- ElectroCore INC
Migraine Disorders, Migraine
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00319137
- Testing
- GW274150
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Chronic Migraine Headache
Clinical Exploration of NEUROMARK System in Participants With Chronic Migraine
Clinical exploration of NEUROMARK System in Participants with Chronic Migraine
- Trial name
- NCT06862674
- Testing
- NEUROMARK System
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Neurent Medical
Migraine Disorders
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
The general aim is to evaluate the relative oral bioavailability of BI 44370 TA tablets during and between migraine attacks as well as Safety, Tolerability and Pharmacokinetic
- Trial name
- NCT00743015
- Testing
- BI 44370 TA tablet
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Migraine
The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects
To evaluate pharmacokinetic/pharmacodynamic characteristics and safety of QDX after single oral administration in healthy Korean male subjects
- Trial name
- NCT04401137
- Testing
- Topiramate
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17.
- Trial name
- PIONEER-PEDS2 (NCT04396574)
- Testing
- Lasmiditan
- Where
- 134 sites in United States, Belgium and 13 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Migraine
A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days.
- Trial name
- NCT01981486
- Testing
- PF-05180999 Tablets
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.
- Trial name
- NCT00334178
- Testing
- Laxymig ER (drug)
- Where
- 7 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- Lotus Pharmaceutical